External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>Cassava Sciences is deemed largely worthless with a cult-like retail investor base, making it an attractive target for shorting.</li><li>Their sole asset, simufilam, aims to address Alzheimer's by restoring the shape of misfolded filamin A, but this approach has raised doubts.</li><li>Dr. Hoau-Yan Wang, a longtime scientific collaborator, is indicted for fraud related to grants associated with their trials, raising questions about the company's credibility, alongside scrutiny on CEO Remi Barbier.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Cassava Sciences is deemed largely worthless with a cult-like retail investor base, making it an attractive target for shorting.Their sole asset, simufilam, aims to address Alzheimer's by restoring the shape of misfolded filamin A, but this approach has raised doubts.Dr. Hoau-Yan Wang, a longtime scientific collaborator, is indicted for fraud related to grants associated with their trials, raising questions about the company's credibility, alongside scrutiny on CEO Remi Barbier.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Cassava Sciences Inc (SAVA) - Sunday, Sep 29, 2024

United States

Cassava Sciences, Inc. operates as a clinical-stage biotechnology company. The Company detects and treats neurodegenerative diseases such as alzheimer's. Cassava Sciences serves clients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00